Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00464659
Other study ID # 0629
Secondary ID
Status Completed
Phase N/A
First received April 20, 2007
Last updated December 29, 2015
Start date April 2007
Est. completion date June 2013

Study information

Verified date December 2015
Source University Hospital, Grenoble
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

The main objective of this study is to evaluate the evolution of memory deficit (verbal episodic memory, procedural memory, working memory, short-term memory) in Sleep Apnea Obstructive Syndrome (SAOS) patients after treatment by Continuous Positive Airway Pressure treatment (CPAP). For thus, we will compare memory tests in two separate groups of SAOS patients with "effective " versus "ineffective" ( or sham) CPAP, before and 6 weeks after the beginning of the treatment. Thus we will assess the evolution of memory deficit, the effectiveness of the treatment on the evolution of memory deficit before and 6 weeks after the beginning of the treatment by "effective " versus "ineffective" CPAP.

We feel the results of the tests of memory will show greater memory disorders in patients with SAOS before beginning the treatment rather than six weeks afterwards. Thus we hypothesise that, after the treatment by "effective" CPAP, the patients with SAOS will have greater improvement of their memory disorders than those treated by "sham CPAP".


Description:

We want to assess the evolution, before and 6 weeks after the beginning of the treatment, of the significant differences of the performances of the various memory tests evaluating several forms of memory (episodic memory, working memory, short-term memory and procedural memory) according to the treatment for patients with SAOS (effective versus sham).


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date June 2013
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Major patients,

- agreeing,

- diagnosed suffering from the SAOS,

- regulation by the specialist in a treatment by CPAP,

- patients do not begin the treatment

- affiliated to the social security,

- fluent in French.

Exclusion Criteria:

- Patients presenting severe depressive disorders (HADS score>19),

- intellectual deterioration (MMS< 28),

- a functional failure of the dominant arm upper limb inhibiting realization of graphic tasks,

- an associated oxygen treatment,

- suffering from cancer,

- cerebro-vascular accident,

- pregnant or nursing women,

- adult under supervision or trusteeship,

- patients already included in another research protocol or in period of exclusion,

- antidepressant and anxiolytic treatment.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Effective CPAP
Auto-titrating CPAP machines (Remstar Auto; Philips Respironics, Murrysville, PA) provided by a home care company (Bastide Medical, France). Pressure was set between 6 and 14 cm of water
Sham CPAP
Similar CPAP machine delivering a 4 cm of water pressure that was too low to suppress sleep respiratory events.

Locations

Country Name City State
France Laboratoire EFCR-Functional Cardio-Respiratory Exploration Laboratory Grenoble Isere

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Grenoble

Country where clinical trial is conducted

France, 

References & Publications (4)

Beebe DW, Gozal D. Obstructive sleep apnea and the prefrontal cortex: towards a comprehensive model linking nocturnal upper airway obstruction to daytime cognitive and behavioral deficits. J Sleep Res. 2002 Mar;11(1):1-16. Review. — View Citation

Engleman HM, Douglas NJ. Sleep. 4: Sleepiness, cognitive function, and quality of life in obstructive sleep apnoea/hypopnoea syndrome. Thorax. 2004 Jul;59(7):618-22. Review. — View Citation

Farré R, Hernández L, Montserrat JM, Rotger M, Ballester E, Navajas D. Sham continuous positive airway pressure for placebo-controlled studies in sleep apnoea. Lancet. 1999 Apr 3;353(9159):1154. — View Citation

Naëgelé B, Launois SH, Mazza S, Feuerstein C, Pépin JL, Lévy P. Which memory processes are affected in patients with obstructive sleep apnea? An evaluation of 3 types of memory. Sleep. 2006 Apr;29(4):533-44. — View Citation

See also
  Status Clinical Trial Phase
Terminated NCT00283309 - Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes Phase 4
Completed NCT05462977 - Rhythmically Entrained Exercise in Community-Dwelling Older Adults N/A
Withdrawn NCT01637168 - Comparison of the Panax Ginseng + Associations to Ginkgo Biloba in the Treatment of Cognitive Function Disorders Phase 3